Treatment of plague: promising alternatives to antibiotics

被引:60
作者
Anisimov, Andrey P. [1 ]
Amoako, Kingsley K.
机构
[1] State Res Ctr Appl Microbiol & Biotechnol, Lab Plague Microbiol, Dept Infect Dis, Obolensk 142279, Moscow Region, Russia
[2] Canadian Food Inspect Agcy, Anim Dis Res Inst, Lethbridge, AB T1J 3Z4, Canada
关键词
D O I
10.1099/jmm.0.46697-0
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Plague still poses a significant threat to human health, and interest has been renewed recently in the possible use of Yersinia pestis as a biological weapon by terrorists. The septicaemic and pneumonic forms are always lethal if untreated. Attempts to treat this deadly disease date back to the era of global pandemics, when various methods were explored. The successful isolation of the plague pathogen led to the beginning of more scientific approaches to the treatment and cure of plague. This subsequently led to specific antibiotic prophylaxis and therapy for Y. pestis. The use of antibiotics such as tetracycline and streptomycin for the treatment of plague has been embraced by the World Health Organization Expert Committee on Plague as the 'gold standard' treatment. However, concerns regarding the development of antibiotic-resistant Y. pestis strains have led to the exploration of alternatives to antibiotics. Several investigators have looked into the use of alternatives, such as immunotherapy, non-pathogen-specific immunomodulatory therapy, phage therapy, bacteriocin therapy, and treatment with inhibitors of virulence factors. The alternative therapies reported in this review should be further investigated by comprehensive studies of their clinical application for the treatment of plague.
引用
收藏
页码:1461 / 1475
页数:15
相关论文
共 175 条
[1]   Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis [J].
Achtman, M ;
Zurth, K ;
Morelli, C ;
Torrea, G ;
Guiyoule, A ;
Carniel, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (24) :14043-14048
[2]  
AFANASEV MI, 1903, HUMAN PLAGUE
[3]  
ALBIZO J M, 1970, Infection and Immunity, V2, P229
[4]   Virulence as a target for antimicrobial chemotherapy [J].
Alksne, LE .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (08) :1149-1159
[5]   Statins, inflammation, and sepsis - Hypothesis [J].
Almog, Y .
CHEST, 2003, 124 (02) :740-743
[6]   Prior statin therapy is associated with a decreased rate of severe sepsis [J].
Almog, Y ;
Shefer, A ;
Novack, V ;
Maimon, N ;
Barski, L ;
Eizinger, M ;
Friger, M ;
Zeller, L ;
Danon, A .
CIRCULATION, 2004, 110 (07) :880-885
[7]   Innate immunity for biodefense: A strategy whose time has come [J].
Amlie-Lefond, C ;
Paz, DA ;
Connelly, MP ;
Huffnagle, GB ;
Dunn, KS ;
Whelan, NT ;
Whelan, HT .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2005, 116 (06) :1334-1342
[8]   Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis [J].
Anderson, GW ;
Worsham, PL ;
Bolt, CR ;
Andrews, GP ;
Welkos, SL ;
Friedlander, AM ;
Burans, JP .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1997, 56 (04) :471-473
[9]  
Ando H, 2000, J PHARMACOL EXP THER, V294, P1043
[10]   Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis [J].
Andrews, GP ;
Strachan, ST ;
Benner, GE ;
Sample, AK ;
Anderson, GW ;
Adamovicz, JJ ;
Welkos, SL ;
Pullen, JK ;
Friedlander, AM .
INFECTION AND IMMUNITY, 1999, 67 (03) :1533-1537